Business Context and Reporting Period
This Form 8-K, filed on September 17, 2018, by Halfmoon Parent, Inc. (a wholly owned subsidiary of Cigna Corporation), reports the completion of a significant debt offering. The filing details the entry into material definitive agreements to finance the pending acquisition of Express Scripts Holding Company.
Key Financial Metrics and Debt Structure
The company completed an offering of $21.0 billion in aggregate principal amount of Senior Notes. The proceeds are designated to fund the cash consideration for the Express Scripts acquisition, repay Express Scripts' indebtedness, and cover transaction fees. The debt structure is as follows:
- 18-Month Floating Rate Notes (2020): $1.0 billion (LIBOR + 0.350%)
- 2-Year Fixed Rate Notes (2020): $1.75 billion (3.200%)
- 3-Year Floating Rate Notes (2021): $1.0 billion (LIBOR + 0.650%)
- 3-Year Fixed Rate Notes (2021): $1.25 billion (3.400%)
- 5-Year Floating Rate Notes (2023): $0.7 billion (LIBOR + 0.890%)
- 5-Year Fixed Rate Notes (2023): $3.1 billion (3.750%)
- 7-Year Fixed Rate Notes (2025): $2.2 billion (4.125%)
- 10-Year Fixed Rate Notes (2028): $3.8 billion (4.375%)
- 20-Year Fixed Rate Notes (2038): $2.2 billion (4.800%)
- 30-Year Fixed Rate Notes (2048): $3.0 billion (4.900%)
The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period, as this is a transactional report rather than a periodic financial statement.
Material Changes and Transaction Mechanics
The primary material change is the incurrence of $21.0 billion in new debt obligations. Key mechanics include:
- Use of Proceeds: Primarily for the Express Scripts acquisition and related debt repayment.
- Mandatory Redemption: All notes except the 30-Year Fixed Rate Notes are subject to special mandatory redemption if the acquisition is not consummated by September 4, 2019, or if Cigna notifies the trustee it will not pursue the deal.
- Collateral: Proceeds from mandatorily redeemable notes must be held in segregated collateral accounts until the acquisition is consummated and the notes are guaranteed by Cigna and Express Scripts.
- Guarantees: Upon consummation of the acquisition, the notes are required to be guaranteed by Cigna Corporation and Express Scripts.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the offering and the forward-looking nature of the acquisition. Significant risks and contingencies identified include:
- Regulatory Approval: The transaction is contingent on obtaining necessary regulatory approvals, which may impose conditions reducing anticipated benefits.
- Integration Risks: Potential difficulties in integrating the businesses of Cigna and Express Scripts, including retention of key personnel and management distraction.
- Registration Default Penalty: If the company fails to file a registration statement for an exchange offer or shelf registration by specified deadlines, the annual interest rate on the notes will increase by 0.25% per 90-day period, up to a maximum of 1.00%.
- Market and Operational Risks: Risks include changes in government regulations (e.g., Medicare), medical cost management, and general economic conditions.
Investor Verification Checklist
- Verify the status of regulatory approvals for the Cigna-Express Scripts merger.
- Confirm the timeline for the mandatory redemption date (September 4, 2019) and the likelihood of the acquisition closing before this date.
- Review the specific terms of the Indenture and Registration Rights Agreement filed as Exhibits 4.1, 4.2, and 4.3.
- Monitor for any announcements regarding a "Registration Default" which would trigger interest rate penalties.
- Assess the impact of the $21.0 billion debt load on the combined company's leverage ratios post-merger.